ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Michigan Scientist David Beer Sought Retraction Of Potti’s NEJM Paper Over Misuse Of His Data

July 30, 2010

Dietary Interventions Reduce Breast Cancer Risk In Trials

May 27, 2005

ODAC To Advise FDA on First Biosimilars Application Jan. 7

December 19, 2014

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

FDA says official spoke on own behalf in admonition to The Cancer Letter. Association of Health Care Journalists asks FDA official to rescind her rebuke.

March 18, 2005

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012